97300 ⎘
Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen Agonist effect on antigen
Antibody-Based Depletion of Antigen-Presenting Cells and Dendritic Cells
#1502Anti-cMet antibody
#1503PD-1 antibodies
#1504Anti-platelet membrane glycoprotein VI monoclonal antibody
#1505Monoclonal antibody SC104 and derivative thereof specifically binding to a sialyltetraosyl carbohydrate as a potential anti-tumor therapeutic agent
#1506Nucleic acids encoding monoclonal antibodies to programmed death ligand 1 (PD-L1)
#1507SAM-6 VARIANTS, TARGET AND METHODS OF USE
#1508Anti-notch3 agonist antibodies and their use in the treatment of notch3-related diseases
#1509Use of B Cell Expansion Agents in Generating Antibodies
#1510Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof
#1511REGULATION OF LYMPHOCYTES AND USES THEREFOR
#1512Use of Agonists of Integrin Alpha 5 for Inducing the Osteogenic Differentiation of Mesenchymal Stem Cells
#1513Fusion Polypeptides Capable of Activating Receptors
#1514ANTI-TRKB MONOCLONAL ANTIBODIES AND USES THEREOF
#1515Interleukin 10 receptor, (IL-10R) antibodies
#1516Human antigen binding proteins that bind β-Klotho, FGF receptors and complexes thereof
#1517Methods of treating cancer by administering antibodies to CD200
#1518HVEM/BTLA, HVEM/CD 160 and HVEM/gD cis complexes and methods of use
#1519ADAM-15 antibodies and immunogenic peptides
#1520Human IgM antibodies, and diagnostic and therapeutic uses thereof particularly in the central nervous system
#1521Therapeutic compositions for treatment of ocular inflammatory disorders
#1522HUMAN IgM ANTIBODIES, AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF PARTICULARLY IN THE CENTRAL NERVOUS SYSTEM
#1523Anti-TrkB antibodies
#1524Anti-c-Met antibody
#1525Receptor modulators
#1526Method for administering homeopathically potentiated antibodies against mediator of inflammation
#1527Anti-CXCR4 antibodies
#1528Modulators
#1529Methods of identifying anti-inflammatory compounds
#1530Therapeutic Binding Molecules
#1531Antibodies against CDCP1 for the treatment of cancer
#1532Anti-Mpl antibodies
#1533Methods for inducing or enhancing an immune response by administering agonistic GITR-binding antibodies
#1534TIE COMPLEX BINDING PROTEINS
#1535Humanized anti-CDCP1 antibodies
#1536Monoclonal antibody capable of binding to anexelekto, and use thereof
#1537Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
#1538Ex vivo methods for targeting or depleting acute myeloid leukemia cancer stem cells
#1539METHODS OF MODULATING THE OX40 RECEPTOR TO TREAT CANCER
#1540AXL antibodies
#1541Immunoglobulin Fc polypeptides
#1542COMPOSITIONS AND METHODS FOR MODULATING IMMUNE RESPONSES
#1543MEANS AND METHODS FOR ENHANCING DIFFERENTIATION OF HAEMATOPOIETIC PROGENITOR CELLS
#1544EphA2 AGONISTIC MONOCLONAL ANTIBODIES AND METHODS OF USE THEREOF
#1545IMMUNE SYSTEM PROGRAMMING THROUGH B7-DC
#1546USE OF TRKB ANTIBODIES FOR THE TREATMENT OF RESPIRATORY DISORDERS
#1547Crystal structures and methods using same
#1548Anti-CXCR4 antibodies
#1549EPHA2 MONOCLONAL ANTIBODIES AND METHODS OF USE THEREOF
#1550Recombinantly produced antibody
#1551Prevention and treatment of synucleinopathic and amyloidogenic disease
#1552Methods of decreasing tumor volume and reducing tumor burden using TNF-receptor-coupling agents
#1553Agonist antibodies against TSHR
#1554Compositions and methods for diagnosing and treating prostate cancer
#1555Targeted binding agents directed to KDR and uses thereof—035
#1556Antibodies to insulin-like growth factor I receptor
#1557MOLECULES AND METHODS FOR MODULATING LOW-DENSITY-LIPOPROTEIN RECEPTOR-RELATED PROTEIN 6 (LRP6)
#1558GFRALPHA3 AND ITS USES
#1559REVERSIBLY INHIBITED ANTIBODIES FOR IMMUNE CELL STIMULATION
#1560Methods of promoting antitumor immunity by administering CD40 agonists and alpha-galactosyl ceramide
#1561Anti-FGFR3 antibodies and methods using same
#1562Method of treating disorders of the cardiovascular system and a pharmaceutical agent
#1563Fusion polypeptides capable of activating receptors
#1564HUMAN ANTIBODIES AGAINST HUMAN FAS AND THEIR USE
#1565Treatment of leukemias and chronic myeloproliferative diseases with antibodies to EphA3
#1566Immune modulation via C-type lectin
#1567Method of treating a pathological syndrome and a pharmaceutical agent
#1568Apelin peptides and methods of use
#1569MDL-1 USES
#1570INHIBITORS FOR GROWTH HORMONE AND RELATED HORMONES, AND METHODS OF USE THEREOF
#1571Method of treating a disorder or condition of viral etiology
#1572Ligands of HVEM for treating hematologic malignancies
#1573Method of inhibition of vascular development using an antibody
#1574Humanized L243 antibodies
#1575Humanized anti-HLA-DR antibodies
#1576Anti-EGFR family antibodies, bispecific anti-EGFR family antibodies and methods of use thereof
#1577Fully human antibodies against human 4-1BB
#1578Method for generation of immunoglobulin sequences
#1579Method for administering homeopathically potentized antibody
#1580KLOTHO BETA
#1581Anti-MDL-1 antibodies
#1582Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders
#1583AGONIST TRKB ANTIBODIES AND USES THEREOF
#1584LINGO binding molecules and pharmaceutical use thereof
#1585EPHA2 AGONISTIC MONOCLONAL ANTIBODIES AND METHODS OF USE THEREOF
#1586COMPOSITIONS AND METHODS FOR THE INHIBITION OF CRIPTO / GRP78 COMPLEX FORMATION AND SIGNALING
#1587METHODS OF MODULATING HVEM, BTLA AND CD160 CIS COMPLEX RESPONSE OR SIGNALING ACTIVITY WITH SOLUBLE LIGHT POLYPEPTIDE SEQUENCES
#1588Compositions and Methods for Treating Pancreatic Tumors
#1589Antibodies inhibiting c-Met dimerization and uses thereof
#1590Anti-Notch3 agonist antibodies and their use in the treatment of Notch3-related diseases
#1591Secreted proteins
#1592MONOCLONAL ANTIBODY DIRECTED AGAINST THE HUMAN LDL RECEPTOR
#1593ANTIBODIES TO CD40
#1594TrkB Agonists for Treating Autoimmune Disorders
#1595Antibodies to CXCL13
#1596TCR-independent activation of T cells
#1597THERAPEUTIC USES OF TIM-3 MODULATORS
#1598Antibodies to c-Met
#1599Uses of mammalian cytokines and agonists; related reagents
#1600Nucleic acids encoding a heme binding protein polypeptide
#1601Antibody Substituting for Function of Blood Coagulation Factor VIII
#1602MODULATING NEURONAL OUTGROWTH VIA THE MAJOR HISTOCOMPATIBILITY COMPLEX CLASS I (MHC I) MOLECULE
#1603Antibodies to the alpha-7 nicotinic receptors and methods of treating inflammatory disorders with the same
#1604Angiogenic and immunoglobic applications of anti cd160 specific compounds obtainable from mab cl 1-r2
#1605Methods of using death receptor ligands and cd20 antibodies
#1606TOXIN CONJUGATED EPH RECEPTOR ANTIBODIES
#1607METHODS OF USING CD40 BINDING AGENTS
#1608Therapeutic compositions and methods
#1609CONTROL CIRCUITRY FOR PROVIDING AN INTERFACE BETWEEN CONNECTABLE TERMINAL AND PERIPHERAL DEVICE CIRCUITRY
#1610Structural isomers of sc(Fv)2
#1611METHODS FOR TREATING UNWANTED WEIGHT LOSS OR EATING DISORDERS BY ADMINISTERING A TRKB AGONIST
#1612CD 40 Binding Molecules and CTL Pepetides for Treating Tumors
#1613Methods of promoting remyelination of central nervous system axons by administrating sHIgM22
#1614INHIBITORS OF T-DARPP FOR USE IN COMBINATION ANTI-CANCER THERAPIES
#1615Methods of identifying anti-inflammatory compounds
#1616NOVEL COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE RELATED DISEASES
#1617Therapeutic compositions and methods
#1618Sp35 antibodies and uses thereof
#1619LYMPHOCYTE SURFACE RECEPTOR THAT BINDS CAML AND METHODS OF USE THEREOF
#1620Stimulation of Toll-Like Receptors on T Cells
#1621Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
#1622B-CELL REDUCTION USING CD37-SPECIFIC AND CD20-SPECIFIC BINDING MOLECULES
#1623Pharmaceutical compositions containing sc(Fv)2
#1624Method for identifying diabetic patients at increased risk for pathological complications
#1625Method for treating cancer using anti-Wnt2 monoclonal antibodies and siRNA
#1626Agonist anti-trkC antibodies and methods using same
#1627MOUSE GLUCOCORTICOID-INDUCED TNF RECEPTOR LIGAND IS COSTIMULATORY FOR T CELLS
#1628Treatment of Conditions Involving Demyelination
#1629Antibodies that bind CD40 and methods of treating cancer and enhancing immune responses
#1630MEMBRANE MOLECULE EXPRESSED SPECIFICALLY IN ACTIVATED PLASMACYTOID DENDRITIC CELL
#1631COMPOSITIONS AND METHODS FOR MODULATING IMMUNE RESPONSES
#1632Immunoglobulin variants and uses thereof
#1633EPHB3-specific antibody and uses thereof
#1634ANTI EPHB4 ANTIBODIES AND ANTIBODY FRAGMENTS
#1635Combination therapies employing GITR binding molecules
#1636Nucleic acid molecules which encode antibodies that bind CD40
#1637Antibodies
#1638FGFR AGONISTS
#1639Anti-platelet membrane glycoprotein VI monoclonal antibody
#1640Antibodies to toll-like receptor-2
#1641ICAM-1 binding antibodies
#1642Nucleic acids encoding B7-H4, a T cell immunoregulatory molecule
#1643Therapeutic use of anti-tweak receptor antibodies
#1644Polynucleotides encoding fully human antibodies against human 4-1BB
#1645Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
#1646Ligand for G-protein coupled receptor FPRL2
#1647Methods of treating cancer by administering antibodies to CD200
#1648ANTI-PLATELET MEMBRANE GLYCOPROTEIN VI MONOCLONAL ANTIBODY
#1649Composition comprising humanized antibody HBBK4 for the treatment of cancer and the use thereof
#1650Methods for treating autoimmune diseases using B7-H4 polypeptides and fragments thereof
#1651Antibodies that bind human protein tyrosine phosphatase beta (HPTPβ)
#1652B7-H3 and B7-H4, Novel Immunoregulatory Molecules
#1653SP35 antibodies and uses thereof
#1654FcGammaRIIB Specific Antibodies and Methods of Use Thereof
#1655ANTIBODIES TO HUMAN SOMATOSTATIN RECEPTOR AND METHODS OF USE
#1656Monoclonal thyroid stimulating or blocking antibodies, peptide sequences corresponding to their variable regions, and their uses in diagnostic, preventive and therapeutic medicine
#1657Cytotoxicity mediation of cells evidencing surface expression of CD44
#1658Use of B Cell Expansion Agents in Generating Antibodies
#1659Methods for Treating Cancer Using Agents That Inhibit Wnt16 Signaling
#1660Activation of Human Antigen-Presenting Cells Through CLEC-6
#1661TIE1-BINDING LIGANDS
#1662Therapeutic Strategy for Treating Autoimmune and Degenerative Diseases
#1663Inflammation treatment, detection and monitoring via TREM-1
#1664Antibodies to complementary peptides of thrombin or portions thereof
#1665IL-1F6 polypeptides
#1666Human DR4 antibodies and uses thereof
#1667COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY LUNG DISEASE
#1668Cytotoxicity mediation of cells evidencing surface expression of CD44
#1669USE OF CD23 ANTAGONISTS FOR THE TREATMENT OF NEOPLASTIC DISORDERS
#1670USE OF CD23 ANTAGONISTS FOR THE TREATMENT OF NEOPLASTIC DISORDERS
#1671USE OF CD23 ANTAGONISTS FOR THE TREATMENT OF NEOPLASTIC DISORDERS
#1672Agents that engage antigen-presenting cells through dendritic cell asialoglycoprotein receptor (DC-ASGPR)
#1673COMPOUNDS
#1674NOVEL GLYCOSYLATED PEPTIDE TARGET IN NEOPLASTIC CELLS
#1675B7-H3 and B7-H4, novel immunoregulatory molecules
#1676USE OF CD23 ANTAGONISTS FOR THE TREATMENT OF NEOPLASTIC DISORDERS
#1677Methods of modulating CD200 receptors
#1678Genetic products differentially expressed in tumors and the use thereof
#1679IL-17A/F heterologous polypeptides and therapeutic uses thereof
#1680Anti-Notch3 antibodies
#1681Method of treating a pathological syndrome and a pharmaceutical agent
#1682Polypeptide compounds for inhibiting angiogenesis and tumor growth
#1683Erythropoietin receptor agonists
#1684Cytotoxicity mediation of cells evidencing surface expression of CD44
#1685Aglycosyl anti-CD154 (CD40 ligand) antibodies and uses thereof
#1686Anti-Notch3 agonist antibodies and their use in the treatment of Notch3-related diseases
#1687Method of reducing the activation of Th2 lymphocytes
#1688Monoclonal antibody Sc104 and derivative thereof specifically binding to a sialyltetraosyl carbohydrate as a potential anti-tumor therapeutic agent
#1689Leptin antagonist and method for quantitative measurement of leptin
#1690Optimized dosing with anti-CD4 antibodies for tolerance induction in primates
#1691Erythropoietin receptor extended duration limited agonists
#1692METHODS AND COMPOSITIONS FOR TARGETING RELT
#1693Method of treating a pathological syndrome and a pharmaceutical agent
#1694Method of treating a pathological syndrome and a pharmaceutical agent
#1695Receptor modulators
#1696Methods of using death receptor ligands and CD20 antibodies
#1697Hepatocyte growth factor receptor antagonists and uses thereof
#1698Method of treating a pathological syndrome and a pharmaceutical agent
#1699Method of treating a pathological syndrome and a pharmaceutical agent
#1700Methods for Enhancing Antibody Activity
#1701Compositions and methods for treating inflammatory lung disease
#1702Tumour necrosis factor binding ligands
#1703Tumour necrosis factor binding ligands
#1704Methods of treating cancer by administering antibodies to CD200
#1705METHODS WANTED FOR TREATING UNWANTED WEIGHT LOSS OR EATING DISORDERS BY ADMINISTERING A TRKB AGONIST
#1706GFRα3 polypeptides
#1707Method of treating a pathological syndrome and a pharmaceutical agent
#1708Muscle regeneration compositions and uses therefor
#1709Antibodies to CD40 and methods of treating cancer and enhancing immune responses
#1710EpA2 monoclonal antibodies and methods of use thereof
#1711Method and apparatus for collaborative system
#1712Effect of BST2 on inflammation
#1713Receptor coupling agents and compositions thereof
#1714EphA2 agonistic monoclonal antibodies and methods of use thereof
#1715Immunomodulating tumor necrosis factor receptor 25 (TNFR25) agonists, antagonists and immunotoxins
#1716Method and composition for treating obesity by targeting cathespin
#1717Use of an active substance binding to CD28 for producing a pharmaceutical composition for the treatment of B-CLL
#1718GITR-binding antibodies
#1719Antibody reactive with human toll like receptor 3
#1720Secreted proteins
#1721Compositions and methods including a recombinant human MAB that promotes CNS remyelination
#1722EphA2 agonistic monoclonal antibodies and methods of use thereof
#1723Tumour necrosis factor binding ligands
#1724Molecular determinants of myeloma bone disease and use thereof
#1725Tumor necrosis factor binding ligands
#1726CD37 immunotherapeutics and uses thereof
#1727Anti-TrkB monoclonal antibodies and uses thereof
#1728Compositions and methods for modulating immune responses
#1729Methods for treating lower motor neuron diseases and compositions containing the same
#1730Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
#1731Use of CD23 Antagonists for the Treatment of Neoplastic Disorders
#1732Use of CD23 Antagonists for the Treatment of Neoplastic Disorders
#1733IL-17A/F heterologous polypeptides and therapeutic uses thereof
#1734Methods of modulating CD200 receptors
#1735Tumour necrosis factor binding ligands
#1736Anti-MPL antibodies
#1737Methods for stimulating or enhancing proliferation of non-tumorous cells expressing MUC1 receptors
#1738Method and composition for reducing blood sugar levels or fat storage by targeting cathepsin
#1739GFRalpha3 and its uses
#1740Humanized L243 antibodies
#1741Tumour necrosis factor binding ligands
#1742Compositions and methods for diagnosing and treating prostate cancer
#1743Aglycosyl anti-CD154 (CD40 ligand) antibodies and uses thereof
#1744Tumour necrosis factor binding ligands
#1745Polypeptides that bind an anti-tissue factor antibody and uses thereof
#1746Agonist antibodies
#1747Techniques and compositions for diagnosis and treatment of cancer (muci)
#1748USE OF CD23 ANTAGONISTS FOR THE TREATMENT OF NEOPLASTIC DISORDERS
#1749Tumour necrosis factor peptide binding antibodies
#1750Tumour necrosis factor binding ligands
#1751Tumour necrosis factor binding ligands
#1752Anti-HGF-R antibodies and their use
#1753Fibroblast growth factor receptors and methods for their use
#1754Lymphocyte surface receptor that binds CAML and methods of use thereof
#1755B7-DC binding antibody
#1756Mouse glucocorticoid-induced TNF receptor ligand is costimulatory for T cells
#1757Methods of treating cancer and enhancing immune responses with antibodies that bind CD40
#1758Therapeutic binding molecules
#1759Ligand for G-protein coupled receptor FPRL2 and uses thereof
#1760Method of inhibition of vascular development using an antibody
#1761Methods for treating cancer using anti-Wnt2 monoclonal antibodies and siRNA
#1762Compositions and methods useful for the diagnosis and treatment of heparin induced thrombocytopenia/thrombosis
#1763Immunoglobulin variants and uses thereof
#1764Methods and compositions for modulating tumor growth
#1765Immunoglobulin variants and uses thereof
#1766Antibodies to Tie1 ectodomain
#1767Modulation of immunoglobulin production and atopic disorders
#1768Cancer therapy using beta glucan and antibodies
#1769Use of an active substance binding to CD28 for producing a pharmaceutical composition for the treatment of B-CLL
#1770Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
#1771Optimized dosing with anti-CD4 antibodies for tolerance induction in primates
#1772Antibodies to insulin-like growth factor I receptor
#1773Induction of anti-tumor ctl immunity through in vivo triggering of 4-1bb and/or cd40
#1774Pharmaceutical composition and method for activating macrophage using the same
#1775Antibodies to insulin-like growth factor I receptor
#1776GFRalpha3 and its uses
#1777Polymer-bound antibody cancer therapeutic agent
#1778Agonist antibodies
#1779Nucleic acids encoding B7-H4, a T cell immunoregulatory molecule
#1780Mammalian EPO mimetic CH1 deleted mimetibodies, compositions, methods and uses
#1781Lymphocyte surface receptor that binds caml and methods of use thereof
#1782Fusion polypeptides capable of activating receptors
#1783Targeted drug delivery using EphA2 or EphA4 binding moieties
#1784Method for screening FGFR-4 agonists
#1785EphA2 agonistic monoclonal antibodies and methods of use thereof
#1786Tie1-binding ligands
#1787Use of discoidin domain receptor 1 (DDR1) and agents that affect the DDR1/collagen pathway
#1788Fully human antibodies against human 4-1BB
#1789Methods for treating taxol-induced sensory neuropathy
#1790Bispecific antibodies for inducing apoptosis of tumor and diseased cells
#1791Anti-FcRn antibodies for treatment of auto/allo immune conditions
#1792Selective inhibition of toll-like receptor-2
#1793Therapeutic binding molecules
#1794Antibodies to c-Met
#1795Uses of mammalian cytokines and agonists; related reagents
#1796Method and system for matching entities in an auction
#1797Methods and compositions for treating cancer using P2RX2 inhibitors
#1798Binding agonist for treatment of neurological and other disorders